Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 6

Results For "litigation"

59 News Found

Bayer posts higher sales, profit in first quarter
News | May 11, 2022

Bayer posts higher sales, profit in first quarter

Company's net income rose by 57.5 percent to 3.291 billion euros in Q1


Sluggish exports to cap pharma revenue growth at 9% this fiscal
News | November 17, 2021

Sluggish exports to cap pharma revenue growth at 9% this fiscal

A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.


Dr Reddy’s Labs announces U.S. FDA approval for Lenalidomide capsules
Drug Approval | October 19, 2021

Dr Reddy’s Labs announces U.S. FDA approval for Lenalidomide capsules

The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg


Max Healthcare to set up a 500-bed capacity hospital in Delhi
Healthcare | August 28, 2021

Max Healthcare to set up a 500-bed capacity hospital in Delhi

This facility will integrate with existing Max hospitals and create a 2,300-bed contiguous medical hub spread over 23 acres. The first phase is to be ready by 2024


US district court favours Pharmacyclics against Natco on Imbruvica
News | August 20, 2021

US district court favours Pharmacyclics against Natco on Imbruvica

In 2018 NATCO and Alvogen had filed an Abbreviated New Drug Application (ANDA) with PIV certification for the generic version of the product


Alkem launches Ibuprofen and Famotidine tablets in US
News | August 07, 2021

Alkem launches Ibuprofen and Famotidine tablets in US

Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg


Alkem launch two drugs in US
News | August 04, 2021

Alkem launch two drugs in US

Ibuprofen and Famotidine tablets approved by FDA


NATCO Pharma receives USFDA approval for Lenalidomide capsules
Policy | May 24, 2021

NATCO Pharma receives USFDA approval for Lenalidomide capsules

NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.


Bayer delivers robust performance despite pandemic
News | February 26, 2021

Bayer delivers robust performance despite pandemic

The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.